List of Excipients in Branded Drug KIRKLAND SIGNATURE ANTI DIARRHEAL

« Back to Dashboard

Generic Drugs Containing KIRKLAND SIGNATURE ANTI DIARRHEAL

Company	Ingredient	NDC	Excipient
Costco Wholesale Company	loperamide hydrochloride	63981-224	ANHYDROUS LACTOSE
Costco Wholesale Company	loperamide hydrochloride	63981-224	CARNAUBA WAX
Costco Wholesale Company	loperamide hydrochloride	63981-224	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in KIRKLAND SIGNATURE ANTI DIARRHEAL?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
1	CARNAUBA WAX
1	CELLULOSE, MICROCRYSTALLINE

Kirkland Signature Anti-Diarrheal Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Kirkland Signature Anti-Diarrheal is an over-the-counter loperamide hydrochloride product positioned as a low-cost private-label alternative to branded Imodium. Its commercial value comes from efficient tablet manufacture, broad retail distribution, high repeat demand, and low active-ingredient cost. The main opportunities are incremental dosage forms, differentiated excipient systems, improved tolerability, travel packaging, and channel-specific products rather than pharmaceutical patent exclusivity.

What active ingredient does Kirkland Signature Anti-Diarrheal contain?

Kirkland Signature Anti-Diarrheal contains loperamide hydrochloride, generally at 2 mg per caplet. Loperamide is an antidiarrheal opioid-receptor agonist that acts primarily in the gastrointestinal tract and is marketed for symptomatic control of acute nonspecific diarrhea. FDA labeling directs adult and pediatric users aged 6 years and older to follow maximum daily-dose limits and discontinue use when symptoms persist beyond the labeled period.[1]

Product attribute	Kirkland Signature Anti-Diarrheal
Active ingredient	Loperamide hydrochloride
Typical strength	2 mg per caplet
Product category	OTC antidiarrheal
Dosage form	Solid oral caplet or tablet
Primary indication	Temporary control of diarrhea
Likely retail channel	Warehouse club and private-label retail
Regulatory pathway	OTC monograph or monograph-aligned product
Orange Book status	Generally not applicable to the OTC product
Biosimilar exposure	None
Primary competitive reference	Imodium A-D and store-brand loperamide products

The exact inactive-ingredient declaration and physical presentation can vary by manufacturer, packaging revision, or contract-manufacturing arrangement. The commercial analysis therefore focuses on the standard 2-mg solid oral formulation and the excipient functions disclosed for loperamide caplets.

What excipients are used in Kirkland Signature Anti-Diarrheal?

The disclosed excipient system for loperamide caplets commonly includes microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, povidone, colloidal silicon dioxide, magnesium stearate, talc, and permitted colorants. These materials support direct compression or a closely related tableting process.

Excipient	Primary technical function	Commercial relevance
Microcrystalline cellulose	Filler, dry binder, compression aid	Supports robust low-dose tablet manufacture
Pregelatinized starch	Binder, filler, disintegrant	Improves compactibility and breakup
Croscarmellose sodium	Superdisintegrant	Promotes rapid tablet disintegration
Povidone	Binder and granulation aid	Improves powder cohesion and content uniformity
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and reduces manufacturing variability
Magnesium stearate	Lubricant	Reduces sticking and ejection force
Talc	Processing aid, anti-adherent	Supports tablet manufacture and surface properties
FD&C Blue No. 1 and D&C Yellow No. 10	Colorants	Provides product identification and brand differentiation

The excipient strategy is conventional and cost-efficient. Loperamide is present at a low mass relative to the total tablet, so the formulation must maintain uniform distribution of the active ingredient across high-volume compression runs. Microcrystalline cellulose, pregelatinized starch, povidone, and colloidal silicon dioxide create a practical balance between flow, compactibility, hardness, and disintegration.

How does the excipient system support commercial-scale manufacturing?

The formulation is designed around manufacturing reliability rather than therapeutic differentiation.

Content uniformity

A 2-mg loperamide dose creates a low-dose blend problem. Uniform distribution depends on particle-size control, ordered mixing, segregation prevention, and validated blend hold times. Povidone and microcrystalline cellulose can improve powder cohesion, while colloidal silicon dioxide supports flow.

The main manufacturing risks are:

• Segregation of loperamide from larger excipient particles.
• Over-lubrication from excessive magnesium stearate.
• Variable tablet hardness from changes in compression force.
• Slow disintegration caused by excess lubricant or high tablet density.
• Color variation from uneven distribution of dye-containing components.

These risks are manageable with standard pharmaceutical process controls and do not require a proprietary excipient platform.

Tablet robustness

Warehouse-club products face extended storage, shipping, bulk handling, and repeated consumer access. Microcrystalline cellulose and pregelatinized starch provide mechanical strength. Talc and magnesium stearate reduce tooling friction and tablet defects.

The formulation must avoid excessive hardness. A caplet that resists breakage but disintegrates slowly can fail dissolution or consumer-use expectations. Croscarmellose sodium provides a counterbalance by accelerating water penetration and tablet breakup.

Product identification

Colorants have a limited technical role but provide commercial value. A colored caplet helps distinguish the product from other household medicines and can support brand recognition. Color may also help separate loperamide from other Kirkland Signature products stored in the same medicine cabinet.

A color-free version could reduce regulatory and consumer objections associated with synthetic dyes, but it would remove a low-cost identification feature. A two-SKU strategy could address both preferences.

What excipient-led commercial opportunities exist?

The strongest opportunities are reformulations that improve user experience without changing the loperamide active ingredient.

1. Dye-free loperamide caplets

A dye-free caplet would target consumers who avoid FD&C and D&C colorants. The commercial change is simple: replace the colorant system with a white or naturally colored tablet while preserving the same active strength and release profile.

Potential benefits include:

• Cleaner-label positioning.
• Access to dye-avoidance consumers.
• Lower complexity in colorant sourcing.
• Easier alignment with retailer wellness programs.

Potential constraints include weaker visual differentiation and the need to maintain product identification through imprinting, shape, and packaging.

2. Orally disintegrating tablets

An orally disintegrating loperamide product could address consumers who lack convenient access to water while traveling or working. The formulation would require a different excipient architecture, likely involving highly porous fillers, stronger superdisintegrants, taste-masking agents, and moisture-protective packaging.

Commercial advantages include:

• Travel and emergency-use positioning.
• Faster perceived onset of administration.
• Accessibility for consumers who have difficulty swallowing caplets.
• Premium pricing relative to standard caplets.

The central formulation challenge is taste. Loperamide can require taste masking, and ODT products have higher sensitivity to moisture, friability, and packaging cost.

3. Chewable tablets

Chewable loperamide could extend the product into a more consumer-oriented format. It would require flavoring, sweeteners, taste masking, and a texture system that avoids grittiness or excessive powderiness.

The product could target:

• Travelers.
• Adult consumers who dislike swallowing tablets.
• Retailers seeking a differentiated private-label alternative.
• Adult caregivers managing short-term diarrhea episodes.

Chewable products carry a greater risk of accidental overuse because they can resemble confectionery. Packaging and labeling would need to preserve clear dosing instructions and warnings.

4. Blister packaging

Blister packaging is an excipient-independent opportunity with significant commercial value. It can improve dose tracking, portability, tamper evidence, and travel convenience compared with a bottle.

A blister SKU could be marketed for:

• Travel medicine kits.
• Workplace first-aid cabinets.
• Airport and convenience channels.
• Emergency preparedness.
• Single-person household use.

The tradeoff is higher packaging cost per dose. A dual strategy could retain bottles for warehouse-club value packs and introduce blisters for higher-margin convenience channels.

5. Moisture-protective packaging

A higher-barrier bottle, induction seal, or desiccant-equipped package may improve stability where the formulation is sensitive to moisture. This is especially relevant for ODTs, chewables, and rapidly disintegrating tablets.

For standard caplets, packaging upgrades are unlikely to create meaningful therapeutic differentiation but may reduce complaints related to softening, sticking, or tablet damage in humid climates.

6. Excipient simplification

A simplified excipient system could reduce procurement complexity and support a dye-free or allergen-conscious claim. The primary candidates for review are:

• Colorants.
• Talc.
• Povidone.
• Pregelatinized starch.
• Magnesium stearate.

Simplification must preserve blend uniformity, tablet hardness, disintegration, dissolution, and shelf life. Removing a material without replacing its function can create new manufacturing or quality risks.

What FDA regulatory status applies to Kirkland Signature Anti-Diarrheal?

Loperamide is regulated as an OTC antidiarrheal active ingredient under FDA’s OTC drug framework. FDA’s final monograph for antidiarrheal drug products identifies the conditions under which active ingredients, labeling, dosage, and indications can be marketed without an individual approved new drug application, subject to applicable requirements.[2]

The product must comply with:

• Drug Facts labeling.
• Active-ingredient and purpose statements.
• Age and dosing directions.
• Warnings concerning persistent diarrhea, fever, bloody stool, mucus, and certain pediatric uses.
• Tamper-evident packaging requirements.
• Current good manufacturing practice requirements.
• Applicable facility registration and listing obligations.

A formulation change that remains within the applicable monograph conditions may be operationally simpler than a novel drug development program. A substantially new dosage form, indication, delivery technology, or drug-device combination could require a different regulatory assessment.

What is the Orange Book status of Kirkland Signature Anti-Diarrheal?

Kirkland Signature Anti-Diarrheal is generally not an Orange Book-centered product. The FDA Orange Book primarily identifies approved prescription drug products and certain approved nonprescription products approved through an NDA pathway. An OTC monograph product ordinarily does not generate the same reference-listed-drug and Paragraph IV framework associated with an NDA-approved branded drug.[3]

The commercial result is important:

• No branded NDA patent estate normally controls the standard monograph-compliant loperamide caplet.
• No conventional Paragraph IV strategy is expected for the basic store-brand product.
• Competitive advantage depends on cost, supply, packaging, shelf placement, retailer access, and consumer trust.
• Product-specific formulation patents would need to cover a genuine technical improvement, not merely the use of standard excipients in a routine caplet.

When does Kirkland Signature Anti-Diarrheal lose exclusivity?

Kirkland Signature Anti-Diarrheal does not have meaningful product exclusivity comparable to a newly approved prescription drug. Loperamide has been marketed for decades, and multiple manufacturers sell equivalent OTC products.

Its practical market protection comes from:

• Costco distribution.
• Kirkland Signature brand recognition.
• Retail pricing.
• Package size and availability.
• Supplier qualification.
• Manufacturing scale.
• Consumer familiarity.

A new entrant can generally compete with an equivalent loperamide product if it satisfies FDA requirements and obtains commercial distribution. The barriers are operational rather than patent-based.

What patent protection covers loperamide and its formulations?

The core loperamide molecule is long off patent. Routine caplet excipients such as microcrystalline cellulose, croscarmellose sodium, povidone, colloidal silicon dioxide, and magnesium stearate are established pharmaceutical materials and do not create a proprietary barrier by themselves.

Potentially protectable subject matter could include:

• A novel orally disintegrating loperamide matrix.
• A specific taste-masking system.
• A controlled-release delivery platform.
• A moisture-stable chewable composition.
• A unique combination product.
• A new method of use supported by clinical evidence.
• A manufacturing process that solves a defined content-uniformity or stability problem.

A patent claim directed only to combining loperamide with conventional fillers, binders, disintegrants, and lubricants would face substantial novelty and obviousness challenges. Commercial diligence should distinguish a true formulation patent from routine excipient selection.

What generic entry risks exist for Kirkland Signature Anti-Diarrheal?

Generic entry risk is already structurally high because the product competes in an established OTC market. The main risk is not a future patent cliff. It is substitution by:

• Walmart, CVS, Walgreens, Amazon, and grocery private labels.
• Generic loperamide products from Perrigo, Dr. Reddy’s, Amneal, and other manufacturers.
• Imodium A-D promotions.
• Retailer migration to lower-cost contract suppliers.
• New delivery formats with stronger consumer convenience.
• Products using alternative packaging or larger count sizes.

The basic caplet has limited differentiation. A supplier with lower conversion cost, stronger quality metrics, or more reliable inventory can displace an incumbent even without changing the formulation.

Which companies compete with Kirkland Signature Anti-Diarrheal?

The competitive landscape includes both branded and private-label products.

Competitor group	Examples	Main competitive lever
Branded loperamide	Imodium A-D	Brand trust, clinical familiarity, broad distribution
Mass-retail private labels	CVS Health, Walgreens, Walmart, Target	Price and convenience
E-commerce products	Amazon Basic Care and marketplace brands	Search visibility, price, subscription purchasing
Generic pharmaceutical suppliers	Perrigo, Amneal, Dr. Reddy’s and others	Manufacturing cost and retail supply
Alternative antidiarrheals	Bismuth subsalicylate products	Different active ingredient and consumer positioning

Costco’s advantage is high-volume traffic and the ability to sell large count packages at low unit prices. Its exposure is concentrated in warehouse-club economics: out-of-stock events, supplier changes, package-size decisions, and limited shelf space.

What licensing deals affect Kirkland Signature Anti-Diarrheal?

No widely disclosed product-specific licensing arrangement is central to the standard Kirkland Signature loperamide caplet. Private-label OTC products are commonly manufactured under supply, contract-manufacturing, or private-label arrangements rather than marketed under a public drug-development license.

The commercially important agreements are likely to concern:

• Finished-dose manufacturing.
• Quality and release testing.
• Packaging and artwork control.
• Product liability allocation.
• Forecasting and minimum purchase volumes.
• Change-control approval.
• Recall responsibilities.
• Supply continuity and alternate-site qualification.

For an acquirer or competing supplier, the contract terms may matter more than patent rights. A long-term supply agreement, approved manufacturing site, or retailer qualification can delay market entry even when no patent blocks competition.

What manufacturing and IP barriers affect new entrants?

The main barriers are executional.

Manufacturing barriers

A new supplier must demonstrate:

• Reliable low-dose blend uniformity.
• Acceptable tablet hardness and friability.
• Rapid and consistent disintegration.
• Dissolution performance.
• Stability through the labeled shelf life.
• Controlled color and appearance.
• Scalable packaging operations.
• Compliance with OTC drug cGMP requirements.

Intellectual-property barriers

The standard product has limited IP protection. Risk rises when a competitor introduces:

• A patented ODT platform.
• A novel taste-masking system.
• A protected blister or dose-delivery design.
• A combination with a separately protected active ingredient.
• A proprietary manufacturing process with enforceable claims.

Freedom-to-operate work should cover active-ingredient patents, formulation patents, packaging patents, trademark rights, and supplier-owned know-how.

What revenue exposure does the product create?

Kirkland Signature Anti-Diarrheal is unlikely to represent material revenue exposure for Costco on a standalone basis because OTC medicines are low-price products with limited per-unit margin. Its value is indirect:

• High-margin basket attachment.
• Warehouse traffic.
• Member convenience.
• Private-label penetration.
• Seasonal and travel demand.
• Low-cost health-and-wellness positioning.

For a manufacturer, the opportunity can be more significant because one supply agreement may cover multiple private-label retailers. A standardized 2-mg loperamide platform can support several customer-specific packages with limited formulation change.

The most attractive expansion is a product family:

1. Standard bottle caplets for value.
2. Small blister packs for travel.
3. Dye-free caplets for label-sensitive consumers.
4. ODT or chewable formats for premium pricing.
5. Combination travel kits with oral rehydration products, subject to regulatory and labeling review.

How strong is the patent estate for Kirkland Signature Anti-Diarrheal?

The patent estate is weak or immaterial for the conventional product. The active ingredient is mature, the dosage form is conventional, and the excipients are widely used. The defensible assets are more likely to be:

• Kirkland Signature trademark rights.
• Retailer access.
• Supplier qualification.
• Manufacturing know-how.
• Packaging scale.
• Procurement economics.
• Consumer data and merchandising capability.

A differentiated reformulation could create a stronger patent position, but patent value would depend on clinical or technical evidence showing a meaningful advantage over conventional loperamide caplets.

Key Takeaways

• Kirkland Signature Anti-Diarrheal is a low-cost OTC loperamide hydrochloride product, typically containing 2 mg per caplet.
• Its excipient system is conventional and optimized for content uniformity, tablet strength, flow, lubrication, and rapid disintegration.
• The core product has little practical patent or exclusivity protection.
• Orange Book and Paragraph IV issues are generally secondary to OTC monograph compliance and private-label supply arrangements.
• The strongest commercial opportunities are dye-free products, ODTs, chewables, blister packs, and travel-oriented packaging.
• Supplier qualification, manufacturing reliability, retailer access, and unit economics are more important than molecule-level IP.
• A differentiated delivery system could support new patent filings, but routine excipient substitutions would offer weak patent protection.
• Biosimilar risk is not relevant because loperamide is a small-molecule OTC drug.
• The most scalable strategy is a common loperamide formulation platform with multiple packaging and dosage-form variants.

FAQs

Is Kirkland Signature Anti-Diarrheal the same as Imodium?

The products generally contain the same active ingredient, loperamide hydrochloride, at the same 2-mg strength. Inactive ingredients, tablet design, packaging, labeling presentation, and quality specifications may differ.

Can a company patent a new loperamide excipient formulation?

Yes, but the formulation must satisfy patentability requirements. A routine combination of loperamide with established fillers, binders, disintegrants, and lubricants is vulnerable to obviousness challenges. A demonstrated technical improvement creates a stronger basis for protection.

Is Kirkland loperamide suitable for children?

FDA labeling for loperamide products includes age-specific restrictions and warnings. Use must follow the product’s current Drug Facts label and applicable pediatric directions.[1]

Does Kirkland Signature Anti-Diarrheal require an FDA-approved NDA?

A monograph-compliant OTC loperamide product may be marketed under the applicable OTC framework rather than through a conventional NDA. A novel indication, formulation, or delivery system may require a different regulatory pathway.

What is the best premium reformulation opportunity?

An orally disintegrating, taste-masked, moisture-protected loperamide product has the clearest premium opportunity. It targets travel, convenience, and swallowing-related needs while creating more formulation differentiation than a standard caplet.

References

1. U.S. Food and Drug Administration. (2024). Loperamide hydrochloride drug facts and labeling requirements. https://www.fda.gov
2. U.S. Food and Drug Administration. (2024). Antidiarrheal drug products for over-the-counter human use: Final monograph. 21 C.F.R. Part 335. https://www.ecfr.gov
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda
4. U.S. Food and Drug Administration. (2024). Current good manufacturing practice regulations for finished pharmaceuticals. 21 C.F.R. Parts 210-211. https://www.ecfr.gov